DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) today announced new data that provide important insights into the mechanisms of TEPEZZA™ (teprotumumab-trbw), illustrating its ...
This Phase 3b/4 post‑marketing study, officially titled “A Phase 3b/4, Double-masked, Randomized, International, Parallel-assignment, Multicenter Trial in Patients With Thyroid Eye Disease to Evaluate ...
Credit: Shutterstock. Tepezza is a human insulin-like growth factor-1 receptor inhibitor. The Indications and Usage section of the Tepezza ® (teprotumumab-trbw) prescribing information has been ...
Tepezza is a prescription drug used to reduce the symptoms of thyroid eye disease (TED) in adults. The price of Tepezza can vary based on your insurance coverage, treatment plan, and pharmacy used. A ...
Concerning reports indicate the newly-approved Thyroid Eye Disease (TED) medication Tepezza could cause hearing loss and tinnitus. TED is the most common orbital disorder in adults, with a ...
DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) today announced new pooled efficacy data from the Phase 2 and 3 clinical trials of TEPEZZA™ (teprotumumab-trbw) showing that the ...
Please provide your email address to receive an email when new articles are posted on . The COVID-19 pandemic has abruptly affected drug manufacturing in the United States. This now includes the ...
-- Additional Horizon data accepted as a poster presentation at ENDO 2020 summarize the first U.S.-based assessment of the GO-QOL questionnaire and demonstrate the significant burden of Thyroid Eye ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results